The risk of hepatocellular carcinoma (HCC) in patients with autoimmune hepatitis (AIH) is unclear. We conducted a systematic review and meta-analysis of the incidence of HCC and associated risk factors among patients with AIH.
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A utoimmune hepatitis (AIH) occurs globally and is characterized by interface hepatitis, hypergammaglobulinemia, and autoantibodies. [1] [2] [3] [4] [5] [6] [7] Clinical manifestations of AIH range from no symptoms to severe acute hepatitis, and rarely fulminant hepatic failure. 5, 8 Approximately one-third of patients with AIH have evidence of cirrhosis at the time of initial diagnosis. 3, 4 Additionally, patients with AIH progress to cirrhosis at variable rates (ranging from 0.1% to 8.1% annually) despite treatment with immunosuppressive therapies. [9] [10] [11] [12] In the United States, the combination of rising incidence of hepatocellular carcinoma (HCC) in both men and women and a low 5-year survival rate has made HCC the fastest growing cause of cancer-related death.
The American Association for the Study of Liver Diseases (AASLD) guidelines recommends HCC surveillance of high-risk patient groups (defined as those with an annual HCC risk of 1.5% or higher). 16 Cirrhosis is a known precursor for HCC in more than 80%-90% of cases. 13 AIH with cirrhosis has been associated with an increase in HCC risk; however, estimates of HCC risk among patients with AIH in cohort studies have varied widely. [17] [18] [19] [20] The European Association for the Study of Liver Diseases guidelines for AIH recommend HCC screening in patients with underlying cirrhosis. 20 However, AASLD guidelines while acknowledging HCC risk may be present make no recommendation for surveillance for patients with AIH cirrhosis per AASLD guidelines. 16 There has not been a systematic effort to consolidate and critically evaluate the evidence regarding the risk of HCC in patients with AIH. Furthermore, studies have reported different and inconsistent findings of determinants other than cirrhosis in increasing the risk for HCC. 19 We performed a systematic review and metaanalysis to estimate the incidence of HCC in patients with AIH, and to examine demographic, clinical, biochemical, and treatment-related factors associated with HCC risk in AIH.
Methods
We performed the study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines and MOOSE guidelines with an a priori study protocol.
21,22

Search Strategy
We searched PubMed and Embase databases from inception up to June 2016 for original research studies regardless of language or design using a combination of MESH and free text terms for AIH and liver cancer (search strategy in Supplementary Table 1) . Additionally, we manually searched reference lists of relevant articles for further studies.
Study Selection
Two investigators (A.T. and L.H.K.) independently determined study eligibility and any disagreements were resolved after discussion with a senior investigator (F.K.). Studies were eligible for inclusion if they fulfilled the following criteria: (1) cohort study design (prospective or retrospective), (2) study population included at least 20 patients with AIH, (3) provided incidence rate of HCC or sufficient raw data to calculate incidence rates, and (4) patients with AIH did not have additional etiologies for liver disease (eg, hepatitis B, hepatitis C). If multiple articles were published using the same cohort, we used the study with the most complete data on the largest number of patients.
Data Extraction and Study Quality Assessment
Two independent reviewers (A.T. and L.H.K.) used standardized data collection forms to extract the following from each study: publication date, authors, country where the study was performed, follow-up years, number of participants, study design, sample size, mean age, sex, methods and intervals for HCC screening if performed, methods used for diagnosing AIH and HCC, liver disease severity or cirrhosis at AIH diagnosis and at the time of HCC diagnosis (if available), and risk factors associated with HCC. We classified patients as subjects with cirrhosis based on authors' definition (of cirrhosis) or histology with stage 3 or 4 fibrosis. Further classification of decompensated cirrhosis (ascites, variceal bleeding, or hepatic encephalopathy) was recorded when available. Any data discrepancy was resolved by referring back to the original studies. Authors of studies were contacted for further clarification when necessary.
Two investigators (A.T. and L.H.K.) independently determined study eligibility and assessed quality with a modified version of the Newcastle-Ottawa quality assessment scale in 3 main areas: (1) selection process of cohorts, (2) similarity and comparability between cohorts, and (3) ascertainment of the outcome of interest. Disagreements were resolved with a third investigator (F.K.).
Statistical Methods
For each study, we recorded or calculated incidence rates of HCC per 1000 person-years with 95% confidence intervals (CI) based on the event rates in relation to the duration of follow-up. We calculated pooled incidence rates and 95% CI, using a Poisson distribution. Meta-analysis models were conducted using the log incidence rates of HCC and corresponding CIs with a random-effects model. We assessed the between-study heterogeneity using I 2 statistic, and used I 2 values of 25%, 50%, and 75% as evidence of low, moderate, or high levels of heterogeneity, respectively. We used a correction factor of 0.5 for both the number of HCC cases and total person-years of follow-up in instances when HCC counts were zero. 23 We assessed for publication bias with the funnel plot, Begg test, and Egger test.
We conducted subgroup analyses based on presence of cirrhosis, sex, continent, and source population (ie, single center, multiple centers, general population). We conducted sensitivity analyses by excluding low-quality studies and abstracts, studies with zero HCC cases, and retrospective studies.
We conducted statistical analyses with Stata version 13.1 (StataCorp, College Station, TX). Tests were 2-tailed and P < .05 was considered significant.
Results
Our search strategy identified 811 articles. Of these, 59 were retrieved for detailed evaluation. We identified 15 articles that used data from 5 cohorts (1 abstract and 2 papers from a cohort in Sweden, 11,24,25 1 abstract and 2 papers from a cohort in Japan, 26 ,27 2 papers from a cohort in the UK, 19 ,28 1 abstract and 1 paper from a different cohort in the United Kingdom, 29, 30 and 4 papers from a cohort in the United States 17, [31] [32] [33] ). In each instance we used the most recent paper that met criteria for inclusion in our analysis; these studies reported the most complete data on the largest number of patients from each cohort. 9, 15, 17, 11, 27 A total of 25 studies, involving 6425 patients with AIH, met our selection criteria and were included in the metaanalysis (between reviewer kappa, 0.92). A total of 20 studies were published as full papers and 5 were reported only as abstracts ( Figure 1 ). Of the 25 studies, 5 were performed in North America, 12 in Europe, 7 in Asia, and 1 in Australia. We did not find any studies from South America or Africa. A total of 4 studies were prospective, 4 were both retrospective and prospective, and the remaining 17 were retrospective cohort in design (Table 1) . Most studies used liver biopsy and the International Autoimmune Hepatitis guidelines to establish the diagnosis of AIH, and radiology or pathology for HCC diagnosis. The method of AIH diagnosis was not mentioned in 5 out of 6 studies published only as abstracts. None of the included studies reported external funding sources.
Eight of the 25 studies were comparative (comparative groups included national population, local population, and patients with primary biliary cholangitis [PBC]). 11, 18, [34] [35] [36] [37] [38] [39] We assessed study quality with a modified Newcastle Ottawa scale. Scores ranged from 3 to 7 (with a maximum score of 9). The median scores were 6 and 5 for comparative and noncomparative studies, respectively (Supplementary Table 2 ).
Baseline Characteristics
The median cohort size was 170 patients (range, 25-1721). Patients were followed for a median of 8.0 years (range, 3.3-16.0). Most patients with AIH were women (80.4%; range, 61.6%-91.7%). The mean age of patients at the time of study enrollment was 46.1 years (range, 36.0-62.0 years). In 22 studies that reported cirrhosis status, 32.4% (median; range, 6.3%-100%) of patients had cirrhosis at the time of AIH diagnosis. Based on 6 studies that reported concurrent autoimmune 
Hepatocellular Carcinoma Incidence Rate in Autoimmune Hepatitis
Of the 6528 patients included in the analysis, 118 patients developed HCC during a median follow-up of 8.0 years (53,026 total person-years). A total of 9 patients from 3 studies had HCC at the time of initial AIH diagnosis or cohort entry and were excluded from HCC incidence calculations. 18, 38, 40 The pooled HCC incidence rate was 3.06 (95% CI, 2.22-4.23) per 1000 personyears, with moderate heterogeneity between the studies (I 2 ¼ 51.5%; Figure 2 ). The range of HCC incidence in individual studies was from 0 to 11.34 per 1000 person-years.
Hepatocellular Carcinoma Incidence Rate in Patients With Autoimmune Hepatitis Cirrhosis
A total of 16 studies examined HCC incidence in patients with evidence of cirrhosis at the time of AIH diagnosis. The pooled HCC incidence rate in patients with AIH cirrhosis was 10.07 per 1000 person-years with low between-study heterogeneity (95% CI, 6.89-14.70; I 2 ¼ 48.8%; Figure 3A ). The range of HCC incidence for this subgroup was from 0.80 to 29.76 per 1000 person-years.
A total of 13 studies reported HCC incidence among patients without cirrhosis at AIH diagnosis. The pooled HCC incidence rate was 1.14 per 1000 person-years (95% CI, 0.60-2.17; I 2 ¼ 23.3%; Figure 3B ). A total of 16 studies reported cirrhosis status at the time of HCC diagnosis. Of 93 patients with HCC, 92 had evidence of cirrhosis. Of these, 22 patients (23.7%) did not have cirrhosis at the time of initial AIH diagnosis but developed cirrhosis during follow up.
Hepatocellular Carcinoma Incidence Rate in Autoimmune Hepatitis by Sex
In the 11 studies examining the incidence of HCC by sex, the pooled HCC incidence rate was 3.13 per 1000 person-years (95% CI, 1.88-5.18) in women and 4.65 per 1000 person-years (95% CI, 2.69-8.03) in men, with low to moderate between-study heterogeneity (I 2 ¼ 64.8% women; I 2 ¼ 23.3% men; Figure 4A ).
Hepatocellular Carcinoma Incidence Rate in Autoimmune Hepatitis by Continent
The pooled annual incidence rate of AIH was higher in studies performed in Asia (5.06 per 1000 person-years; 95% CI, 3.54-7.23; I 2 ¼ 0.0%; 7 studies) compared with 
Hepatocellular Carcinoma Incidence Rate in Autoimmune Hepatitis by Source Population
The pooled annual incidence rate of HCC was higher in single specialized tertiary center studies ( Figure 4C ).
Sensitivity Analysis
After excluding 6 studies published only as abstracts, the pooled annual HCC incidence rate decreased to 2.60 per 1000 person-years (95% CI, 1.84-3.66; I 2 ¼ 47.3%) in the remaining 19 studies (Supplementary Figure 1) . The results did not change when we removed 3 studies with zero HCC counts (3.12 per 1000 person years; 95% CI, 2.24-4.34; I 2 ¼ 56.2%; Supplementary  Figure 2) . The pooled HCC incidence rate was 2.98 per 1000 person-years (95% CI, 1.86-4.78) in retrospective, and 3.07 per 1000 person-years (95% CI, 2.05-4.60) in prospective or retrospective/prospective studies. There was low to moderate between-study heterogeneity among the studies (I 2 ¼ 59.3% retrospective; I 2 ¼ 30.6% prospective; Supplementary  Figure 3 ). 
Other Determinants of Hepatocellular Carcinoma
A total of 5 studies used multivariable regression analyses to identify factors associated with the development of HCC in AIH. 30, 39, [44] [45] [46] These studies identified older age, male gender, cirrhosis status at baseline, number of AIH relapses, and alcohol use as independent factors associated with risk of HCC in patients with AIH (Supplementary Table 3) .
Two studies reported the risk of HCC in patients with AIH with overlap syndrome with PBC; the pooled HCC rate was 14.4 per 1000 person years (95% CI, 1.7-51.0). 35, 47 None of the 5 patients with AIH and primary sclerosing cholangitis overlap, reported in 1 study developed HCC. 35 A total of 6 studies reported HCC surveillance but it was not possible to compare the incidence of HCC according to screening status because this information was not provided in most studies. 15, 17, 39, 47, 48 
Publication Bias
Egger plot and Begg plot did not demonstrate significant bias (P values .35 and .12, respectively). The funnel plot did not show significant asymmetry ( Figure 5 ).
Discussion
In this systematic review and meta-analysis, we found that HCC developed at an overall incidence rate of 3.06 per 1000 patient-years (95% CI, 2.22-4.23) among patients with AIH. Cirrhosis was a predominant risk factor for HCC. The incidence of HCC in patients with cirrhosis at time of AIH diagnosis was 10.07 per 1000 patientyears (95% CI, 6.90-14.70). Although HCC was reported to occur in patients who did not have cirrhosis at time of AIH diagnosis, it was a relatively rare and not statistically significant scenario (1.14 per 1000 patientyears; 95% CI, 0.60-2.17).
AASLD guidelines suggest that HCC surveillance is cost-effective if the expected risk of HCC exceeds 1.5% per year. [49] [50] [51] In this meta-analysis, the overall pooled incidence of patients with AIH cirrhosis was 1.007% per year (10.07 per 1000 patient-years). However, the 95% CI nearly encompasses the recommended cutoff value of 1.5% and in 5 of the 16 studies, the annual incidence rate (that reported HCC incidence in patients with AIH cirrhosis) exceeded 1.5%. [43] [44] [45] [46] [47] We also found that almost all patients (92 of 93) who developed HCC had progressed to cirrhosis during their follow-up. Collectively, these data support the importance of regular monitoring of disease severity in AIH with initiation of HCC screening in patients who progress to cirrhosis despite medical management.
Based on published literature, in patients with hepatitis B, HCC incidence varies between 0-7 per 1000 person-years in carriers, 1-10 per 1000 person-years in chronic hepatitis, and 9-54 per 1000 person-years in patients with hepatitis B cirrhosis. 52, 53 The HCC incidence among patients with hepatitis C has been reported to be 1-8 per 1000 person-years in patients with chronic hepatitis and 37-71 per 1000 person-years in patients with cirrhosis. 52 The incidence of HCC among patients with PBC has been reported to be 0-11 per 1000 personyears and in patients with PBC cirrhosis has been reported to be 7-24 per 1000 person-years. [53] [54] [55] [56] [57] [58] The incidence of HCC among patients with PSC is not known but likely very low. 59 Based on our study findings, the risk of HCC in patients with AIH cirrhosis is lower than patients with cirrhosis related to hepatitis B, hepatitis C, or PBC.
Besides cirrhosis, we found several demographic and clinical factors associated with HCC risk. Older age at AIH diagnosis was associated with risk of HCC. Men with AIH had a slightly higher risk of developing HCC than women, Figure 5 . Funnel plot (A) and Egger publication bias plot (B). InIR, natural log of incidence rate.
but the difference was not statistically significant, likely caused by sample size limitations (only 1138 men were included in this analysis and of these 26 developed HCC) and relatively younger age of men at time of AIH diagnosis compared with women. Although the effect of AIH treatment was difficult to assess given the heterogeneity of disease severity in this population, 2 studies suggested that increased frequency of AIH relapses portend increased risk of HCC. Macaron et al 39 found that patients with AIH with concomitant alcohol abuse had 6-fold higher risk of HCC than patients without alcohol use. These data support careful monitoring of patients with AIH, particularly older men, patients with multiple AIH relapses, and those with ongoing alcohol abuse. However, the concomitant presence of primary sclerosing cholangitis was associated with low HCC risk; similar findings were reported in studies of patients with primary sclerosing cholangitis alone. 59 Asian populations have the highest incidence of HCC; in this study we also found a higher HCC risk in Asian patients with AIH than patients in other continents.
14 This increased risk may be related to the older mean age of patients or from other factors, such as aflatoxin exposure.
60,61 Additionally, we found the incidence rates varied by source population. Studies using single tertiary center data found higher rates of HCC than studies using multicenter or country data. This may reflect increased risk of HCC in patients with more complicated or severe disease that were referred to those tertiary centers.
Our study has several limitations related to the available primary studies. All studies had small numbers of patients who developed HCC (n ¼ 0-15), and therefore the incidence rate estimates are likely not precise, particularly in the subgroup analyses. Most studies lacked a comparison cohort and followed patients for relatively short durations. Inconsistent reporting limited our ability to assess the influence of various risk factors. We were also unable to measure the effects of HCC surveillance in this population because this information was not included in most studies.
We used a comprehensive systematic search strategy that included hand searches and searches for unpublished reports. We did not find any evidence of publication bias, providing support to the decision to incorporate gray literature in our study. Additionally, we conducted several subgroup and sensitivity analyses to evaluate HCC incidence rates in various subgroups. The between-study heterogeneity was reduced in the subgroups including prospective and single tertiary centers studies, suggesting that some of the heterogeneity in the HCC incidence rates resulted from differences in study design and source population.
In conclusion, patients with AIH-related cirrhosis are at an increased risk for HCC. HCC surveillance might be cost effective in this population. However, patients with AIH without cirrhosis at index diagnosis, particularly those identified from general populations, are at an extremely low risk of HCC.
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